ライブラリ登録: Guest
Begell Digital Portal Begellデジタルライブラリー 電子書籍 ジャーナル 参考文献と会報 リサーチ集
Journal of Environmental Pathology, Toxicology and Oncology
インパクトファクター: 1.241 5年インパクトファクター: 1.349 SJR: 0.519 SNIP: 0.613 CiteScore™: 1.61

ISSN 印刷: 0731-8898
ISSN オンライン: 2162-6537

Journal of Environmental Pathology, Toxicology and Oncology

DOI: 10.1615/JEnvironPatholToxicolOncol.2016012256
pages 355-364

Inhibition of the p53 Y220C Mutant by 1-Hydroxy-2- Methylanthraquinone Derivatives: A Novel Strategy for Cancer Therapy

Vidhula Ahire
LARIA, iRCM, François Jacob Institute, DRF-CEA, Caen, France; UMR6252 CIMAP, CEA - CNRS– ENSICAEN, Université de Caen Normandie, Caen, France
D. Das
Department of Biotechnology, Siddhaganga Institute, Tumkur
Kaushala Prasad Mishra
Department of Life Sciences, University of Mumbai, Mumbai, India; Nehru Gram Bharati University, Allahabad, UP, India; Foundation for Education and Research, India and BM International Research Centre, Mumbai, India
G. R. Kulkarni
School of Basic Medical Science, University of Pune, Pune- 411007, India
L. Ackland
Centre for Cellular & Molecular Biology, School of Life and Environmental Sciences, Deakin University, Australia

要約

Y220C, a substitution mutation in p53, causes major structural changes in the protein and is known to form a new protein cavity. This cavity is reckoned to accommodate small drug candidates that may play a key role in cancer treatment. Present study was aimed at determining a drug candidate that could inhibit the mutant p53 based on structural drug rationale. Docking of mutated p53 was performed to determine the drug of choice from the derivatives of 1-hydroxy-2- methylanthraquinone exhibiting anti-cancer properties. The cavity had been tested for identification of an accurate position vector for molecular docking studies using structure based drug design. The docked structure was validated using discovery studio 3.5. The best choice of two molecules were obtained by docking in specific solvent for 6 nanoseconds at a temperature of 310 K. Out of a library of compounds, acetamido-2-carboxy-4-dimethylamino-2- hydroxybenzophenone satisfied the ADMET and was found to be a potential target for mutant p53. This ligand binds at the active site of the protein. Results of present study offer a rationale of the lead ligands that can rescue oncogenic p53 by targeting the mutation site. Therefore, it is suggestive that small molecules may serve as an effective and novel anti-cancer drug.


Articles with similar content:

Nitric Oxide Donor and Mimetic Molecules in Cancer Chemotherapy and Chemoprevention
Forum on Immunopathological Diseases and Therapeutics, Vol.1, 2010, issue 4
S. Anand, R. J. Thatcher, Isaac T. Schiefer
Dual Role of p21 in the Progression of Cancer and Its Treatment
Critical Reviews™ in Eukaryotic Gene Expression, Vol.26, 2016, issue 1
Amna Parveen, Whang Wan Kyunn, Muhammad Sajid Hamid Akash, Kanwal Rehman
Inhibitors of Cell Cycle Kinases: Recent Advances and Future Prospects as Cancer Therapeutics
Critical Reviews™ in Oncogenesis, Vol.17, 2012, issue 2
Robert L. Sutherland, Andrew Stone, Elizabeth A . Musgrove
p53 Binding to Target Sites Is Dynamically Regulated Before and After Ionizing Radiation-Mediated DNA Damage
Journal of Environmental Pathology, Toxicology and Oncology, Vol.23, 2004, issue 1
Alex Almasan, Marcela Oancea, Meredith E. Crosby
YY1 PcG function as a Potential cancer Therapeutic Target
Forum on Immunopathological Diseases and Therapeutics, Vol.1, 2010, issue 1-2
Frank Wilkinson, Michael L. Atchison, Antionette Knox, Omozusi Andrews, Arindam Basu, Suchita Hodawadekar, Xuan Pan